Harbour Investments Inc. Boosts Stake in Pfizer Inc. (NYSE:PFE)

Harbour Investments Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 73,287 shares of the biopharmaceutical company’s stock after purchasing an additional 9,216 shares during the quarter. Harbour Investments Inc.’s holdings in Pfizer were worth $2,051,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PFE. Clifford Swan Investment Counsel LLC increased its stake in Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after purchasing an additional 18,611 shares in the last quarter. Cantor Fitzgerald Investment Advisors L.P. purchased a new position in shares of Pfizer in the fourth quarter valued at $16,166,000. First Heartland Consultants Inc. raised its stake in shares of Pfizer by 43.3% during the 4th quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 3,933 shares during the last quarter. ORG Partners LLC boosted its position in shares of Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 44,458 shares in the last quarter. Finally, Kempner Capital Management Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $2,439,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Down 0.3 %

NYSE:PFE traded down $0.09 during trading hours on Tuesday, hitting $28.84. The stock had a trading volume of 16,156,843 shares, compared to its average volume of 38,734,188. The company has a market cap of $163.40 billion, a PE ratio of -480.33, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. The business has a 50 day simple moving average of $28.89 and a two-hundred day simple moving average of $27.98. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $36.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the company posted $0.67 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.68 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.83%. Pfizer’s dividend payout ratio is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.